ArticleAnnals of surgical oncology2026
Prognostic Associations Between Adjuvant Chemotherapy and Survival in T1b-T2N0M0 Medullary Breast Cancer: A Population-Based Study of 2343 Patients.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to explore potential prognostic associations between adjuvant chemotherapy and survival outcomes in patients with T1b-T2N0M0 medullary breast cancer (MBC) who underwent surgical resection (breast-conserving surgery or mastectomy).
methodsUsing the Surveillance, Epidemiology, and End Results (SEER) database (2000-2015), we analyzed 2343 women with pathologically confirmed T1b-T2N0M0 MBC who underwent surgery. Patient characteristics, treatment (chemotherapy, radiotherapy, surgery type), and survival outcomes (overall survival [OS], breast cancer-specific survival [BCSS]) were analyzed. Propensity score matching (1:1) was employed to minimize confounding. Kaplan-Meier analysis and Cox proportional hazards models assessed survival differences and prognostic factors.
resultsAmong 2343 patients (median follow-up 141 months), 1507 (64.3%) received adjuvant chemotherapy. Patients receiving chemotherapy were typically younger (<65 years), more likely to be married, had larger tumors (T1c/T2), and had estrogen receptor-negative disease than those who did not. Multivariable analysis identified adjuvant chemotherapy as an independent favorable prognostic factor for both OS (P < 0.001) and BCSS (P = 0.039). Before and after propensity score matching, chemotherapy significantly improved OS and BCSS (P < 0.05). Subgroup analysis revealed significant survival benefits for patients with T1c-T2 tumors and hormone receptor-negative/human epidermal growth factor receptor 2-negative disease. However, no significant benefit was observed for patients with T1b tumors or hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (P > 0.05).
conclusionsAdjuvant chemotherapy may optimize survival in select patients with T1b-T2N0M0 MBC, though prospective validation is warranted.
Indexed as
Identifiers
41535564What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.